Hypothesis

Resident eosinophils in skeletal muscle sustain an IL-4‑driven regenerative state through an autocrine IL-33‑STAT6 circuit that promotes Notch ligand expression on fibro/adipogenic progenitors (FAPs). With aging, declining stromal IL-33 and rising soluble ST2 break this loop, shifting eosinophils toward an IL-5‑primed, TGF‑β‑secreting, pro‑fibrotic phenotype that drives sarcopenia.

Mechanistic Basis

• Eosinophils express IL-33R (ST2) and, upon IL-33 binding, activate STAT6, which induces transcription of IL-4 and the Notch ligands DLL1/JAG1 [3, 4]
• DLL1/JAG1 signaling in FAPs biases them toward a myogenic-supportive state, enhancing satellite cell activation and myofiber repair [1]
• In the absence of IL-33 signaling, eosinophils retain IL-5 responsiveness; IL-5 priming drives a TGF‑β‑high program that promotes ECM deposition and adipogenic differentiation of FAPs [5]
• Aging reduces stromal IL-33 production and increases soluble ST2, sequestering IL-33 and weakening eosinophil autocrine signaling [7]

Predictions & Experimental Design

1. Loss‑of‑function: Conditional deletion of Il33r (ST2) specifically in eosinophils of young mice will reduce eosinophil IL-4 output, increase intracellular TGF‑β, and diminish Notch ligand expression on FAPs, resulting in delayed muscle regeneration after cardiotoxin injury.
2. Gain‑of‑function: Administration of an IL‑33 agonist or ST2‑Fc fusion protein to aged mice will restore eosinophil STAT6 activity, elevate IL-4/DLL1 levels, shift FAPs toward a myogenic phenotype, and improve grip strength and muscle cross‑sectional area.
3. Readouts: Flow cytometry for intracellular IL-4 vs TGF‑β in eosinophils; immunofluorescence for DLL1/JAG1 on FAPs; histology for central nucleation and fibrosis (Masson’s Trichrome); functional assays (in‑vivo twitch tension).
4. Falsifiability: If IL‑33R deletion does not alter eosinophil cytokine balance or if IL‑33 agonism fails to rescue regenerative outcomes in aged mice, the hypothesis is refuted.

Potential Implications

This mechanism explains why broad anti‑IL‑5 therapies can impair muscle homeostasis while offering a targeted strategy: augmenting eosinophil‑intrinsic IL‑33/STAT6 signaling preserves regenerative functions without expanding pathogenic eosinophils. It also suggests that soluble ST2 levels could serve as a biomarker for eosinophil phenotype skew in aging or chronic inflammatory conditions.